A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

Inclusion criteria

(key):

• Males
• Age 18- 55 years
• Body mass index (BMI) 18.0 kg/m2 to 32.0 kg/m2
• Body weight 55.0 kg to 100.0 kg
• Considered to be in good health
• Nonsmoker
• Content of 14C in urine, whole blood, and/or plasma samples does not exceed the general environmental background level of 14C

Exclusion criteria

(key):

• Clinically significant abnormal medical history or any abnormal finding on physical examination, vital signs, ECG, laboratory tests
• History of cancer that has not been in full remission for >5 years
• Acute illness within 14 days prior to Day 1
• History of significant drug allergies
• History or presence of alcohol or drug abuse
• Recent history of incomplete bladder emptying with voiding or awakening more than once at night to void
• Usual habit of <1 or >3 bowel movements per day
• Exposure to radiation for therapeutic, diagnostic, or occupational reasons within the 12 months prior to Day 1.
• Participation in another clinical study in which a [14C]-labeled drug was administered within 1 year prior to Check-in
• Administration of another investigational medication within 60 days (or 5 half-lives, whichever is longer) prior to Day 1
• Participation in an investigational-device study within 60 days prior to Day 1
• Any ECG abnormality considered to be clinically significant by the Investigator
• QTcF interval >450 msec and QRS interval >120 msec
• Family history of long QT syndrome or of unexplained sudden death in a first-degree relative under 50 years of age
• Documented congenital or acquired long QT syndrome
• Presence of clinically significant hypertension
• Presence of clinically significant hypotension
• Loss or donation of more than 500 mL blood within 60 days prior to the Screening
• Excessive consumption of alcohol
• Use of any live vaccinations within 30 days
• Use/consumption of food or drugs known to be moderate or strong cytochrome P450 3A4 (CYP3A4) inducers or potent CYP3A4 inhibitors within 14 days or 5 half-lives, whichever is longer, prior to RV521 administration